The prostate cancer screening controversy in perspective.
Until long-term ongoing trials show that screening for prostate cancer is beneficial and cost-effective, physicians should focus screening efforts on high-risk patients most likely to benefit from treatment, and inform patients about the pluses and minuses of current screening, diagnostic, and treatment methods.
Vaughn
K W
KW
Department of General Internal Medicine, Cleveland Clinic, USA.
D006801:Humans; D008017:Life Expectancy; D008297:Male; D008403:Mass Screening; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D012307:Risk Factors; D012680:Sensitivity and Specificity
D017430:Prostate-Specific Antigen